| abstract |
The composition used for administration to the lung comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an additive. In one particular form, the particles have an aerodynamic mass median diameter of about 1 μm to about 5 μm, and the fluoroquinolone has a lung half-life of at least 1.5 hours. The composition is useful for treating intrabronchial infections caused by Pseudomonas aeruginosa and the like, and is particularly useful for treating cystic fibrosis. |